Auris Medical Holding AG (NASDAQ:EARS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “
Other research analysts have also issued reports about the stock. Leerink Swann reiterated a “buy” rating and set a $12.00 price target on shares of Auris Medical Holding AG in a research note on Wednesday, June 15th. Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Needham & Company LLC boosted their price objective on shares of Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, August 19th. Finally, JMP Securities downgraded shares of Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a report on Thursday, August 18th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Auris Medical Holding AG has a consensus rating of “Buy” and a consensus target price of $8.88.
Shares of Auris Medical Holding AG (NASDAQ:EARS) traded down 1.14% during mid-day trading on Thursday, hitting $1.74. 88,490 shares of the stock were exchanged. The company has a 50-day moving average of $2.16 and a 200 day moving average of $3.41. Auris Medical Holding AG has a one year low of $1.55 and a one year high of $7.96. The stock’s market cap is $59.73 million.
A number of hedge funds have recently added to or reduced their stakes in EARS. Bellevue Group AG acquired a new stake in shares of Auris Medical Holding AG during the first quarter valued at about $7,897,000. TFS Capital LLC increased its stake in shares of Auris Medical Holding AG by 17.7% in the second quarter. TFS Capital LLC now owns 38,230 shares of the company’s stock valued at $160,000 after buying an additional 5,762 shares during the period. Finally, Advisor Group Inc. acquired a new stake in shares of Auris Medical Holding AG during the second quarter valued at about $277,000. 30.95% of the stock is currently owned by hedge funds and other institutional investors.
Auris Medical Holding AG Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.